同步化疗加后程加速超分割适形放射治疗食管癌

doi:10.3971/j.issn.1000-8578.1813

同步化疗加后程加速超分割适形放射治疗食管癌

Chemotherapy and Late Course Accelerated Hyperfrationation Plus Three Dimensional Conformal Radiotherapy for Esophageal Carcinoma

摘要

摘要: 目的评价同步化疗加后程加速超分割适形放射治疗食管癌的疗效和并发症。方法 54例食管癌患者随机分为二组（适形组与对照组），每组27例，放疗采用6／15MVX线外照射，前2／3疗程常规放射治疗DT40Gy，后1／3疗程分为后程加速超分割适形放射治疗和超分割放疗，2次／天，1．4Gy／次，全疗程总剂量为68Gy，化疗采用LEP方案（四氢叶酸钙，5-氟脲嘧啶和顺铂）。结果适形组与对照组的1、2年生存率分别为85．2%、63．0％和78．0％、59．3%（x²=0．49、0．08，P〉0．05）。结论同步化疗加后程加速超分割适形放射治疗食管癌有提高生存率的趋势，并发症少。

Abstract: Objective 　To evaluate the treatment efficacy and complications of chemotherapy and late course accelerated hyperf ractionation (LCAH) plus three-dimensional conformal radiotherapy (3DCRT) for esophageal carcinoma. Methods 　The 54 patient s with esophageal carcinoma were randomized into two groups : fourty-eight patients received chemotherapy and LCAH Plus 3DCRT (3DCRT group ), 27 patients received chemotherapy plus LCA HR (control group), all patients were given with 6/ 15 MV X-ray total tumors dose was 40 Gy/20f, with conventional fractionation routine during the first two-thirds of the course, and followed by LCAHR plus 3DCRT or LCAHR, per fraction, twice daily, the total does Varied up to 68 Gy, chemotherapy regimen was LFP(CF, 52FU and DDP) . Results 　The 12and 22year survival rates in 3DCRT group and cont rol group were 85. 2 %、63. 0 % and 78. 0 %、59. 3 %(χ2 = 0. 49 、0. 08, P > 0. 05) . Conclusion 　Chemotherapy and LCAHR plus 3DCRT for esophageal carcinoma can improve the survival rate and decrease complications.

HTML全文

参考文献(0)

施引文献

资源附件(0)